These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 7536277

  • 1. [Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
    Yamato H, Yamada K, Koike T, Yoshida M, Tsunogake S, Aoyagi M, Nakamura Y, Watanabe K, Saito K, Enokihara H.
    Rinsho Ketsueki; 1995 Feb; 36(2):128-33. PubMed ID: 7536277
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma].
    Yamamoto K, Nagata K, Morita Y, Hamaguchi H.
    Rinsho Ketsueki; 2002 Jun; 43(6):488-92. PubMed ID: 12134707
    [Abstract] [Full Text] [Related]

  • 4. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
    Saito K.
    Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
    Wang Y, Li W, Chen S, Qiu H, Sun A, Wu D.
    Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493
    [Abstract] [Full Text] [Related]

  • 8. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 9. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T, Kawabata H, Sawaki T, Satoh T, Nakamura T, Iwao H, Nakajima A, Sakai T, Miki M, Fujita Y, Tanaka M, Kawanami T, Masaki Y, Okazaki T, Umehara H.
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].
    Saito K, Furusawa S, Yamada K, Waga K, Aoyagi A, Koike T, Arimura H, Noguchi M, Yamato H, Sakuma H.
    Rinsho Ketsueki; 1995 Mar; 36(3):165-74. PubMed ID: 7540220
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [RAEB in T with monosomy 7 after treatment of severe aplastic anemia with long term G-CSF].
    Kaito K, Otsubo H, Ogasawara Y, Sekita T, Saeki A, Nishiwaki K, Masuoka H, Shimada T, Kobayashi M, Sakai O.
    Rinsho Ketsueki; 1995 Apr; 36(4):365-70. PubMed ID: 7540227
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T, Yasuyama M, Kawauchi K.
    Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
    Nakamura Y, Arai Y, Gunji H, Arai H, Nakamura F, Handa T, Tadokoro J, Maki K, Saito K, Mitani K.
    Rinsho Ketsueki; 2002 Oct; 43(10):960-2. PubMed ID: 12462034
    [Abstract] [Full Text] [Related]

  • 20. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN, Fernández-Jurado A, Martino ML, Diéguez JC, Moreno MV, Quesada JA, Polo B, Cañavate M, Amian A, Prados D.
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.